Alumis Inc. released positive long-term data for its oral psoriasis treatment, envudeucitinib, demonstrating leading skin clearance rates and a favorable safety profile. The company plans to file a New Drug Application in Q4, positioning the drug as a potential market leader, despite an initial negative stock reaction.
Alumis Inc. announced impressive long-term data from its ONWARD3 study for envudeucitinib, an oral treatment for plaque psoriasis. The drug achieved high PASI 100 response rates and maintained skin clearance, surpassing current and experimental treatments. This positive clinical data is a significant catalyst for Alumis, as it plans to file a New Drug Application with the FDA in Q4, potentially leading to market approval and substantial revenue. While the stock initially traded lower, likely due to profit-taking or broader market sentiment, the long-term implications are positive for ALMS, as the drug could become a leading oral therapy for psoriasis and other immune-mediated diseases. The key opportunity for traders lies in the potential for future FDA approval and market penetration.